Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

Share :
Published: 30 Sep 2012
Views: 7765
Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

During a press conference at ESMO 2012 in Vienna Dr Alice Shaw discusses the results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer.


ecancerNews coverage of ESMO 2012